Steven Weiss, MD
Hematology-Oncology · Coral Springs, FLNPI 1730185299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 287 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$966
- Sanofi$386
- Seagen Inc.$338
- Novartis$238
- Merck$233
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,22194%
- Education$3346%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 48 | $1,124 |
| Pfizer | 76 | $966 |
| Sanofi | 13 | $386 |
| Seagen Inc. | 9 | $338 |
| Novartis | 12 | $238 |
| Merck | 12 | $233 |
| Array Biopharma Inc | 11 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $163 |
| AstraZeneca(2 entities) | 9 | $162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $146 |
| Lilly USA, LLC | 7 | $137 |
| Adaptive Biotechnologies Corporation | 4 | $127 |
| Amgen | 6 | $123 |
| Daiichi Sankyo Inc. | 6 | $114 |
| Bayer | 4 | $90 |
| Shire North American Group Inc | 4 | $88 |
| Genentech USA, Inc. | 6 | $85 |
| Astellas Pharma US Inc | 5 | $82 |
| AbbVie | 3 | $74 |
| Eisai Inc. | 4 | $71 |
| Bristol Myers Squibb | 3 | $66 |
| Sobi, Inc | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Myriad Genetic Laboratories, Inc. | 2 | $49 |
| Emmaus Medical, Inc. | 4 | $42 |
| Agios Pharmaceuticals, Inc. | 2 | $41 |
| Clovis Oncology, Inc. | 2 | $38 |
| Foundation Medicine, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| Grifols USA, LLC | 1 | $20 |
| Immunogen, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
Too few hematology-oncology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CerdelgaEliglustat Tartrate | 15 | $484,384 |
| Lenalidomide | 18 | $330,526 |
| JakafiRuxolitinib Phosphate | 15 | $271,852 |
| PomalystPomalidomide | 11 | $240,031 |
| LynparzaOlaparib | 12 | $185,738 |
| VenclextaVenetoclax | 13 | $102,636 |
| Alprazolam | 21 | $305 |
| Gabapentin | 15 | $288 |
| Hydroxyurea | 17 | $276 |
| Anastrozole | 16 | $201 |
| Zolpidem Tartrate | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiCerdelga | $386 | $484,38415 claims |
| Incyte CorporationJakafi | $18 | $271,85215 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $146 | $240,03111 claims |
| AstraZenecaLynparza | $162 | $185,73812 claims |
| AbbVieVenclexta | $74 | $102,63613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Coral Springs
- Isaac LevyPembroke Pines$55K
- Amer RassamTallahassee$11K
- Roger FebresKissimmee$11K
- Meri MuminovicMiramar$6K
- Carlos BarburHialeah$5K
- Bruce StechmillerSt Augustine$0
- Seongseok YunTampa$0
- Peter MoussaTampa$0
- Andrew DeniccoMiami$0
- Robert KilleenHoliday$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.